Physician profile
Michael Ellison
NPI 1861465932
$1,485.21
in general payments reported to CMS, 2019-2025
8 companies · $74.79 in 2025
The $74.79 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.20 · 2020: $322 · 2021: $304 · 2022: $93.52 · 2023: $338 · 2024: $258 · 2025: $74.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $637 · Education: $33.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $637.44 |
| Education | $33.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,026.92 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.77 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $135.79 | 2024 | Tezspire |
| Myriad Genetic Laboratories, INC. | $50.75 | 2023 | Myrisk |
| Pulmonx Corporation | $38.08 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Insmed, INC. | $33.62 | 2025 | Brinsupri, Arikayce |
| Csl Behring | $24.46 | 2019 | |
| United Therapeutics Corporation | $21.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.